A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma

This study is testing whether adding an immunotherapy drug (adebrelimab) to chemotherapy before and after surgery improves outcomes for people with locally advanced esophageal squamous cell cancer — a cancer of the food pipe that has not yet spread to distant organs. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with squamous cell cancer of the esophagus that is locally advanced but can still be removed by surgery - You have not previously received any cancer treatment (chemotherapy, radiation, immunotherapy, or surgery) for your esophageal cancer - You are in good general health (ECOG performance status 0 or 1) - Your blood counts, liver, and kidney function are within acceptable ranges **You may NOT be eligible if...** - Your esophageal cancer has spread to distant organs (metastatic) - You have already received cancer treatment for this diagnosis - You have significant heart, lung, or organ problems that would make surgery unsafe - You have active autoimmune disease or are on immunosuppressive medications Talk to your doctor to see if this trial is right for you.